Clinical Oncology
Volume 22, Issue 6 , Pages 475-485 , August 2010

Medullary Thyroid Carcinoma

  • F. Pacini

      Affiliations

    • Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, University of Siena, Italy
    • Corresponding Author InformationAuthor for correspondence: F. Pacini, Section of Endocrinology & Metabolism, Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy. Tel: +39-057-7585406; Fax: +39-057-7586187.
    • ,
  • M.G. Castagna

      Affiliations

    • Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, University of Siena, Italy
    • ,
  • C. Cipri

      Affiliations

    • Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, University of Siena, Italy
    • ,
  • M. Schlumberger

      Affiliations

    • Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Villejuif, France

Received 3 February 2010 ,Revised 29 March 2010 ,Accepted 4 May 2010.

References 

  1. Schlumberger M, Pacini F. Thyroid tumors. Paris: Edition Nucleon; 2006;313–340. Chapter 18
  2. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. In: International classification of tumours. 2nd ed.. Berlin: Springer-Verlag; 1988;
  3. LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab. 1997;82:39–41
  4. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229:880–887
  5. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88:2070–2075
  6. Przepiorka D, Baylin SB, McBride OW, Testa JR, de Bustros A, Nelkin BD. The human CT gene is located on the short arm of chromosome 11. Biochem Biophys Res Commun. 1984;120:493–499
  7. Pacini F, Fugazzola L, Basolo F, Elisei R, Pinchera A. Expression of calcitonin gene-related peptide in medullary thyroid cancer. J Endocrinol Invest. 1992;15:539–542
  8. Baloch Z, Carayon P, Conte-Devolx B, et al. Guidelines Committee, National Academy of Clinical Biochemistry Laboratory medicine practice guidelines. Calcitonin and RET proto-oncogene mesaurements. Thyroid. 2003;13:68–79
  9. Motté P, Vauzelle P, Gardet P, et al. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies. Clin Chim Acta. 1988;174:35–54
  10. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–460
  11. Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375–376
  12. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994;6:70–74
  13. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 1995;267:381–383
  14. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276:1575–1579
  15. Schuffenecker I, Ginet N, Goldgar D, et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d’Etude des Tumeurs a Calcitonine. Am J Hum Genet. 1997;60:233–237
  16. American Thyroid Association Guidelines Task Force , Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612
  17. Uchino S, Noguchi S, Adachi M, et al. Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas. Jpn J Cancer Res. 1998;89:411–418
  18. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the RET proto-oncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996;81:1619–1622
  19. Schilling T, Bürck J, Sinn HP, et al. Prognostic value of codon 918 (ATG–>ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer. 2001;95:62–66
  20. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682–687
  21. Boi F, Maurelli I, Pinna G, et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:2115–2118
  22. Kudo T, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid. 2007;17:635–638
  23. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:826–829
  24. Rieu M, Lame MC, Richard A, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol. 1995;42:453–460
  25. Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 2001;11:73–80
  26. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab. 1997;82:338–341
  27. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhäusl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab. 1997;82:1589–1593
  28. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol. 2005;91:56–60
  29. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89:163–168
  30. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450–455
  31. Gagel RF, Jackson CE, Block MA, et al. Age-related probability of development of hereditary medullary thyroid carcinoma. J Pediatr. 1982;101:941–946
  32. Leboulleux S, Travagli JP, Caillou B, et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer. 2002;94:44–50
  33. Vasen HF, van der Feltz M, Raue F, et al. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Arch Intern Med. 1992;152:1250–1252
  34. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–5671
  35. Bugalho MJ, Domingues R, Santos JR, Catarino AL, Sobrinho L. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery. 2007;141:90–95
  36. Wiench M, Wygoda Z, Gubala E, et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol. 2001;19:1374–1380
  37. Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab. 2007;92:4725–4729
  38. Gharib H, McConahey WM, Tiegs RD, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc. 1992;67:934–940
  39. Stålberg P, Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg. 2009;33:2234–2243
  40. Wells SA, Farndon JR, Dale JK, Leight GS, Dilley WG. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg. 1980;192:451–458
  41. Stepanas AV, Samaan NA, Hill CS, Hickey RC. Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer. 1979;43:825–837
  42. Fugazzola L, Pinchera A, Luchetti F, et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers. 1994;9:21–24
  43. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005;90:2029–2034
  44. Franc S, Niccoli-Sire P, Cohen R, et al. French Medullary Study Group (GETC)Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol. 2001;55:403–409
  45. Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239–246
  46. Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003;134:890–899
  47. Koopmans KP, de Groot JW, Plukker JT, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524–531
  48. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF, GTE Study Group . Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077–6084
  49. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer. 1996;77:1556–1565
  50. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–1148
  51. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine. Clin Endocrinol. 1998;48:265–273
  52. Fromigué J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:2496–2499
  53. Isozaki T, Kiba T, Numata K, et al. Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. Intern Med. 1999;38:17–21
  54. Lorenz K, Brauckhoff M, Behrmann C, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery. 2005;138:986–993
  55. Chatal JF, Campion L, Kraeber-Bodéré F, et al. French Endocrine Tumor GroupSurvival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705–1711
  56. Scherübl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol. 1990;116:21–23
  57. Orlandi F, Caraci P, Berruti A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol. 1994;5:763–765
  58. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer. 1994;73:432–436
  59. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d’Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 1995;71:363–365
  60. Di Bartolomeo M, Bajetta E, Bochicchio AM, et al. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol. 1995;6:77–79
  61. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer. 1988;62:1899–1903
  62. Bajetta E, Rimassa L, Carnaghi C, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer. 1998;83:372–378
  63. Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase ii study. J Clin Oncol. 2008;28:4708–4713
  64. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794–3801
  65. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol. 2007;25:14065

PII: S0936-6555(10)00172-X

doi: 10.1016/j.clon.2010.05.002

Clinical Oncology
Volume 22, Issue 6 , Pages 475-485 , August 2010

Article Tools

* Image Usage & Resolution